VYNE Therapeutics (VYNE) Debt Ratio (2019 - 2021)

VYNE Therapeutics (VYNE) posted Debt Ratio of 0.25 for Q2 2021, up 11.67% on a QoQ basis from 0.22 in Q1 2021, and down 0.98% year-over-year from 0.25 in Q2 2020.

VYNE Therapeutics (VYNE) Debt Ratio (2019 - 2021) Analysis & Trends

VYNE Therapeutics' Debt Ratio history runs 3 years deep, the most recent figure standing at 0.25 for Q2 2021.

  • Quarterly Debt Ratio fell 0.98% year-over-year to 0.25 in Q2 2021, while the trailing twelve-month figure through Jun 2021 was 0.25 (down 0.98% YoY) and the FY2020 annual result came in at 0.35, down 12.24% from the prior year.
  • Debt Ratio was 0.25 for Q2 2021 at VYNE Therapeutics, up from 0.22 in the prior quarter.
  • Across five years, Debt Ratio topped out at 0.4 in Q4 2019 and bottomed at 0.22 in Q1 2021.
  • A 3-year average of 0.3 and a median of 0.31 in 2020 frame the typical range for Debt Ratio.
  • Peak annual rise in Debt Ratio reached 0.98% in 2021, while the deepest fall reached 31.73% in 2021.
  • VYNE Therapeutics' Debt Ratio stood at 0.4 in 2019, then dropped by 12.24% to 0.35 in 2020, then dropped by 29.61% to 0.25 in 2021.
  • Business Quant data shows VYNE's Debt Ratio at 0.25 in Q2 2021, 0.22 in Q1 2021, and 0.35 in Q4 2020.

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr) Debt Ratio (Qtr)
1 Oculis Holding AG 66,621.14 Bn 66,620.85 Bn - -
2 Nanobiotix 1,915.18 Bn 1,915.11 Bn - 1.41
3 Akari Therapeutics 1,014.18 Bn 1,014.18 Bn - -
4 BeOne Medicines 471.27 Bn 466.48 Bn 1.35 Bn 0.11
5 Vertex Pharmaceuticals 121.81 Bn 114.57 Bn 2.59 Bn -
6 Regeneron Pharmaceuticals 69.58 Bn 60.82 Bn 3.31 Bn 0.05
7 Belite Bio 62.72 Bn 62.72 Bn - -
8 Argenx Se 55.51 Bn 50.33 Bn 1.41 Bn -
9 Revolution Medicines 37.35 Bn 37.35 Bn - -
10 VYNE Therapeutics 1.19 Bn 1.16 Bn - -

Historic Data

Download Data
DateValue
Jun 30, 2021 0.25
Mar 31, 2021 0.22
Dec 31, 2020 0.35
Sep 30, 2020 0.31
Jun 30, 2020 0.25
Mar 31, 2020 0.33
Dec 31, 2019 0.40